Fuji Pharma Co., Ltd. (FRA:FUP)
Germany · Delayed Price · Currency is EUR 9.70
+0.05 (0.52%)
At close: Dec 1, 2025
Fuji Pharma Income Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2016 - 2020 |
| 51,677 | 46,138 | 40,889 | 35,426 | 33,990 | Upgrade | |
Revenue Growth (YoY) | 12.01% | 12.84% | 15.42% | 4.23% | 0.58% | Upgrade |
Cost of Revenue | 30,914 | 28,294 | 24,374 | 20,867 | 19,239 | Upgrade |
Gross Profit | 20,763 | 17,844 | 16,515 | 14,559 | 14,751 | Upgrade |
Selling, General & Admin | 10,953 | 9,231 | 8,331 | 7,355 | 8,340 | Upgrade |
Research & Development | 3,344 | 3,401 | 3,184 | 2,485 | 2,446 | Upgrade |
Amortization of Goodwill & Intangibles | 90 | 337 | 316 | 283 | 278 | Upgrade |
Operating Expenses | 15,769 | 13,963 | 12,656 | 10,781 | 11,402 | Upgrade |
Operating Income | 4,994 | 3,881 | 3,859 | 3,778 | 3,349 | Upgrade |
Interest Expense | -330 | -196 | -121 | -77 | -53 | Upgrade |
Interest & Investment Income | - | - | 77 | 43 | 7 | Upgrade |
Currency Exchange Gain (Loss) | 35 | 74 | 127 | 227 | -48 | Upgrade |
Other Non Operating Income (Expenses) | -242 | 53 | 212 | 39 | -6 | Upgrade |
EBT Excluding Unusual Items | 4,457 | 3,812 | 4,154 | 4,010 | 3,249 | Upgrade |
Gain (Loss) on Sale of Investments | - | 3,118 | - | - | 153 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | 2 | Upgrade |
Asset Writedown | -394 | 572 | 364 | -288 | -33 | Upgrade |
Legal Settlements | - | - | -120 | - | - | Upgrade |
Other Unusual Items | -63 | 772 | - | - | -1 | Upgrade |
Pretax Income | 4,000 | 8,274 | 4,398 | 3,722 | 3,370 | Upgrade |
Income Tax Expense | 1,000 | 2,128 | 963 | 1,026 | 938 | Upgrade |
Net Income | 3,000 | 6,146 | 3,435 | 2,696 | 2,432 | Upgrade |
Net Income to Common | 3,000 | 6,146 | 3,435 | 2,696 | 2,432 | Upgrade |
Net Income Growth | -51.19% | 78.92% | 27.41% | 10.85% | 16.64% | Upgrade |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 27 | Upgrade |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 27 | Upgrade |
Shares Change (YoY) | 0.38% | 0.04% | 0.03% | -9.58% | -13.77% | Upgrade |
EPS (Basic) | 122.93 | 252.81 | 141.35 | 110.98 | 90.52 | Upgrade |
EPS (Diluted) | 122.93 | 252.81 | 141.35 | 110.98 | 90.52 | Upgrade |
EPS Growth | -51.37% | 78.86% | 27.37% | 22.60% | 35.27% | Upgrade |
Free Cash Flow | 3,820 | 1,373 | -1,410 | -5,755 | 2,204 | Upgrade |
Free Cash Flow Per Share | 156.54 | 56.48 | -58.02 | -236.90 | 82.03 | Upgrade |
Dividend Per Share | 45.500 | 42.500 | 37.000 | 35.000 | 29.000 | Upgrade |
Dividend Growth | 7.06% | 14.87% | 5.71% | 20.69% | - | Upgrade |
Gross Margin | 40.18% | 38.67% | 40.39% | 41.10% | 43.40% | Upgrade |
Operating Margin | 9.66% | 8.41% | 9.44% | 10.66% | 9.85% | Upgrade |
Profit Margin | 5.80% | 13.32% | 8.40% | 7.61% | 7.16% | Upgrade |
Free Cash Flow Margin | 7.39% | 2.98% | -3.45% | -16.25% | 6.48% | Upgrade |
EBITDA | 8,959 | 7,561 | 6,882 | 6,523 | 5,455 | Upgrade |
EBITDA Margin | 17.34% | 16.39% | 16.83% | 18.41% | 16.05% | Upgrade |
D&A For EBITDA | 3,965 | 3,680 | 3,023 | 2,745 | 2,106 | Upgrade |
EBIT | 4,994 | 3,881 | 3,859 | 3,778 | 3,349 | Upgrade |
EBIT Margin | 9.66% | 8.41% | 9.44% | 10.66% | 9.85% | Upgrade |
Effective Tax Rate | 25.00% | 25.72% | 21.90% | 27.57% | 27.83% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.